Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series.

ABSTRACT:

Background

Faricimab is a novel anti-vascular endothelial growth factor agent, used to treat patients with neovascular age-related macular degeneration (nAMD). This study assessed efficacy and safety of faricimab in previously treated eyes.

Methods

This retrospective study included previously treated nAMD patients who had received at least three faricimab injections. Baseline data were collected from February 2023 to September 2023, and follow-up data were collected until April 2024. The patients were divided into two cohorts: (1) the "Loaded" cohort, which received four weekly injections prior to treatment extension, and (2) the "Interval-Matched" cohort, which continued on the same treatment interval as their previous regimen. Efficacy was evaluated based on the primary ou

SUBMITTER: Bantounou MA 

PROVIDER: S-EPMC11892307 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature